Disease-modifying therapies enter the World Health Organization Essential Medicines List: A victory now requiring a roadmap of implementation.
In: Multiple sclerosis (Houndmills, Basingstoke, England), Jg. 30 (2024), Heft 1, S. 3-6
editorialOpinion
Zugriff:
Competing Interests: Declaration of Conflicting InterestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship and/or publication of this article: B.Y. and S.V. were Co-Chairs of the MSIF Off-Label Treatments (MOLT) panel. S.V. and D.S. were panel members on MSIF Essential Medicines Panel (MEMP). J.L.D. works as a consultant for Multiple Sclerosis International Federation (MSIF) and has coordinated both MOLT and MEMP panels. MEMP members used recommendations from both MOLT and MEMP guidelines to develop the WHO EML application.
Titel: |
Disease-modifying therapies enter the World Health Organization Essential Medicines List: A victory now requiring a roadmap of implementation.
|
---|---|
Autor/in / Beteiligte Person: | Yamout, BI ; Viswanathan, S ; Laurson-Doube, J ; Sokhi, D |
Zeitschrift: | Multiple sclerosis (Houndmills, Basingstoke, England), Jg. 30 (2024), Heft 1, S. 3-6 |
Veröffentlichung: | 2006- : London : SAGE Publications ; <i>Original Publication</i>: Houndmills, Basingstoke, Hampshire, UK : Stockton Press, c1995-, 2024 |
Medientyp: | editorialOpinion |
ISSN: | 1477-0970 (electronic) |
DOI: | 10.1177/13524585231205970 |
Schlagwort: |
|
Sonstiges: |
|